{"name":"PhaseBio Pharmaceuticals Inc.","slug":"phasebio-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PB1046 Subcutaneous Injection","genericName":"PB1046 Subcutaneous Injection","slug":"pb1046-subcutaneous-injection","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"PB1046 Subcutaneous Injection","genericName":"PB1046 Subcutaneous Injection","slug":"pb1046-subcutaneous-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9UcG9OcEJhQUxzZ1ZrNXRmS05VWjc1aXU4M2FCTGxTSTlZUjI1NGNWNHJQUjVSSG9XVHFhVWYwR2lGWmhwQUh0dTVWVl8yeUhSZjMyLVVqVUsxcFRNX0ZDOU50M2ZYR204eW9Mb1hNUQ?oc=5","date":"2025-07-08","type":"pipeline","source":"The Pharma Letter","summary":"John Lee joins Diagonal as CMO - The Pharma Letter","headline":"John Lee joins Diagonal as CMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBwQWhoU2p1Y1dNS2N0MnhRLUVKRkVOZHVCUE9wN09ZbWdPSDFfeVVDUi03a25fRFVibFBrbXpkVVhBMWpLamNzUDhJa1RZSUdjS2gyWUlDRlFoS2lhSkI5YkRFMURRV25XQmEtcXB1NkF6TEpHcWZhUlpn?oc=5","date":"2025-02-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"Bill Humphries joins MedPharm as CEO - Pharmaceutical Technology","headline":"Bill Humphries joins MedPharm as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPQjgzZW9zNHh6TC1jMXdFdWJoS0g2WUxSeVQ3QWphSWxzTkE5WktIeDQ0OTFBS1h3cW92a01VN01lYi03TnJzSENlaTFOeWN5SG9XS1huSjFjdUREWXRsYkhXSUI2UW5oNHN4X0ZBbGpoUW9Da3VndmdCeDdnUUZiVE0yQlExX19jd0VnS1B0c0JoSnlBcWU3XzMzU0lvLVJ6Yk1OR2lFTQ?oc=5","date":"2024-07-12","type":"trial","source":"Investing.com","summary":"PhaseBio announces bankruptcy plan confirmation - Investing.com","headline":"PhaseBio announces bankruptcy plan confirmation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOeXI2d25iZzRSY0FvaW5hbmMzd3BHQTBDTUVKcU1sSGFjTi1GQjNaZHlrN09zQ1pmRkh3Q19qTFVZN2VwOTkyOHkzd0FHZWhHT3NPdDlVOVQwcHRFRUFIX05KazNyaEw2TlZyN1Z6YzRlMlkxMWk4NWlPbU56ZnotaTVrNV82VTFMMVZaMXpGVlpiM213Rm4zbnYyLVZRWmhmYVBZb3ZzbmxQa2ZLTC1Pa2xvZG5iX2FET0VnWFJDWWc3c3JvUkw1MDl3ZF9zSlUwdzV6Y09RX2J4enpKTjZF?oc=5","date":"2024-04-11","type":"pipeline","source":"PR Newswire","summary":"Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer - PR Newswire","headline":"Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBuM1FfMURoYmVDS1loZUZ3YzMwcUk1bGJQc01NZXhTVzhob3p6ei1jQmNpVUFGSWFRTUpVNEt6UXUzMF94ZHJTMHFTSjdzZkxZYm81aWhJRWlyNFBPdUY4?oc=5","date":"2023-08-11","type":"pipeline","source":"Nature","summary":"People - Nature","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPNWVkV3ZpVmNnNUFfMEdveWt5UU1hNlc5aktKbUlMMkRMMHNoa2RlN2VyQkgzX09teThCWTF1bE1KLUx6UFFBOFl2dXlGcWlFTTgtMVkwbGpoY0VuOEtwX3JSVDNhQXMyRmR3aUNFMEJWeFQtUTE3S1pIVjdGMWJuVW81VGZKeGJ4N2hEcUpueEJHOGpBdTg4WmNBc3ozWmw5bHF0WGJCTHdObU9MQ2FJVExtQndwX29JYlN1T3phV2UtTlNlU3I2YTBpZjFpODkySXNRNjQ4dnZ6YmM5V18xenZwd3FQdEdYeW9sUnNPRQ?oc=5","date":"2023-01-17","type":"trial","source":"Business Wire","summary":"SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals - Business Wire","headline":"SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQOEUyS3JReXNJU3JjTXZ6dGdZRUlTdURVTTItd1duMW91TTVyeF95dlFpQU1OSG5SZzhJSTVJdFNuRXVGYy00MEdqTUcyZ3RpNk1uUXlCRVgxTXZzVGZ2eC14eGR0NXhWRXQ5Z3ZQaU1zcGdXYUVfVG9ISXctMWJhaDJSX0dQM2xLN0cwVjFrSjNwY1pTUTExaWJjZm1TLVF4VjdWN2t1ZXZWczFDclNjZWN3SGhWUQ?oc=5","date":"2022-10-24","type":"trial","source":"BioSpace","summary":"PhaseBio Files for Bankruptcy, Inks Deal to Sell Assets to Unnamed Company (Updated) - BioSpace","headline":"PhaseBio Files for Bankruptcy, Inks Deal to Sell Assets to Unnamed Company (Updated)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPY3lVWldpcmFiY0YxbWFLSkpZMmphcTYyTFp2UFI1NEJWY213V05WWGszSkxwUmd5MXkwMnFaeGsyeXpzVlZ6d1FFRTJOYU15MXUydFJFOEFxS1JLWkFpY2hnQ1hFejVLNkcxOXcycHhRSzh3MWxLcXBJLVB2T0hob0dad01xUjZxMUFSM2FldkNsWHA5UmxkdUtDamY?oc=5","date":"2022-10-23","type":"trial","source":"WSJ","summary":"PhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuit - WSJ","headline":"PhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPWVNabEtuSkdSQVJrNlE1ZEFsdVRPWDc4aENzaWhDUElzUmVYUDF3dHk3XzQ5THhIVWIzbnpPVHNHblRDX1ZvQkNhVFdlM0dmY3ByNWk0QXhhZHpXc05PSTFMRHF6NWxmd245WFN3WkJ2dmp3X09meUVGY3JhVHd5aXQ1bWs1QU5Id3FLcHE5OGFyQmRDNjZj?oc=5","date":"2022-04-18","type":"trial","source":"Yahoo Finance","summary":"Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B - Yahoo Finance","headline":"Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQT05hX2hmQ1dleHRtSk9CNHhkZ3EyWi04NXQyTW9GNFo4cGd6RkhJVWp5UTZnV2Q3aHFUZDVlUGZBeURQSElQdU9yQVpUMFBCUmFBallHZWNhWEg0a2RCMUIzRWlNazZyZDFVeTUtMXd2VS1GV1RiZ18xYk9SRFFZSW5wTlpUc2pYYS1oUHFVajRLZw?oc=5","date":"2021-12-22","type":"trial","source":"Clinical Trials Arena","summary":"PhaseBio suspends Phase IIb pulmonary arterial hypertension therapy trial - Clinical Trials Arena","headline":"PhaseBio suspends Phase IIb pulmonary arterial hypertension therapy trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNXzdhYm9QcnpIaUY3T0xqYWd1aks1U242S25ZX0htYl9VUWMtU0VWbmVhQnpWTFBqYVRiM0hMaW42bEtob01UUjUtLUZoRV9BalZROWlSbXVwOGhPTU1WTUgyLUM2U1htTnRBc0RsSkZqOFBmY3Y4ZkVyMDRVbXVBbHZGcHNSc2x3MEJwQkZSeXk0Z0FKY0N4YVVFekVSa3JSMG13N3NmX1dndw?oc=5","date":"2021-12-21","type":"trial","source":"Fierce Biotech","summary":"PhaseBio blames COVID-19 disruption as cardiovascular study axed - Fierce Biotech","headline":"PhaseBio blames COVID-19 disruption as cardiovascular study axed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPYWFJZmJiUDlOcDRJX3lUcHVOQnhVRFU3Rkh3aDdjVnZXVHhmV3VVcEthZXUzRzcyLS1LNUdlNHBjNWFSejRYMXRpTmZNNTJOZG51TkJ4ZGhyQTZ0RERBaWwyQlZUTHpLajJDM2Yyc3FyWFByVHduTDAtb2lOTEFheTU1MlBNeEs2b0ZWeGcyYlo2VlZi?oc=5","date":"2017-11-28","type":"deal","source":"BioPharma Dive","summary":"AstraZeneca outlicenses Brilinta reversal agent - BioPharma Dive","headline":"AstraZeneca outlicenses Brilinta reversal agent","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}